NCT05013827View on ClinicalTrials.gov

Opinions of Company Representatives About Neuromodulation

CompletedOBSERVATIONAL
Enrollment

39

Participants

Timeline

Start Date

September 2, 2021

Primary Completion Date

September 9, 2021

Study Completion Date

September 9, 2021

Conditions
NeuromodulationPainSurvey
Interventions
BEHAVIORAL

Filling in an online survey

Company representatives are questioned about three aspects: 1) goals in treating patients with neuromodulation for pain, 2) factors that respondents expect to change according to neuromodulation for pain and 3) their definition of success of neuromodulation for pain.

Trial Locations (1)

1090

Vrije Universiteit Brussel, Jette

All Listed Sponsors
lead

Moens Maarten

OTHER

NCT05013827 - Opinions of Company Representatives About Neuromodulation | Biotech Hunter | Biotech Hunter